The Federal Trade Commission reached an agreement with Endo to settle claims that the company blocked the market entry of Opana ER and Lidoderm generics, and then refiled a lawsuit against Allergan and its former subsidiary Watson Laboratories with identical charges.
Source: Drug Industry Daily